Research programme: hydroxynorketamine derivatives - Spirify Pharma
Alternative Names: Hydroxynorketamine derivativesLatest Information Update: 28 Nov 2022
At a glance
- Originator Spirify Pharma
- Class Analgesics; Antidepressants; Small molecules
- Mechanism of Action Amino acid modulators; Serine protease modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Depressive disorders; Pain
Most Recent Events
- 01 Nov 2022 Spirify Pharma enters into a research collaboration with WeLab Barcelona to advance Spirify's proprietary class of analogs of hydroxynorketamine
- 01 Nov 2022 Spirify Pharma has patent protection for modulators of D-serine in USA
- 20 May 2021 Spirify Pharma has patent pending for hydroxynorketamine analogues Worldwide